Leading nephrologists Dr. An De Vriese and Dr. Monnie Wasse join as Company continues clinical advancement
Xeltis, a leading developer of transformative implants that enable the natural creation of living and long-lasting vessels, today announces the appointment of clinical nephrology experts An De Vriese, MD, PhD and Haimanot (Monnie) Wasse, MD, MPH to its Medical Advisory Board (MAB).
An De Vriese is currently Head of the Division of Nephrology and Infectious Disease in AZ Sint-Jan Brugge and Guest Professor at Ghent University, while Monnie Wasse serves as the Interim Chair of the Department of Internal Medicine, and the Chief of Nephrology and Director of Interventional Nephrology at the Rush University Medical Center. Both add considerable clinical nephrology expertise to the Company’s esteemed and decorated MAB and will work alongside current members to offer strategic and clinical guidance as Xeltis advances aXess towards commercialization.
Eliane Schutte, Chief Executive Officer of Xeltis said: “We are pleased that both An and Monnie have chosen to join our Medical Advisory Board, bolstering our already stellar team of advisors. The appointments represent significant validation of the unique and promising nature of our technology from leading experts in the field. Their experience across nephrology and vascular access will be invaluable as we continue to progress aXess through its pivotal trials in the EU and US, with primary readouts for our EU pivotal trial expected in mid-2025.”
An De Vriese, MD, PhD, newly appointed member of the Xeltis Medical Advisory Board, commented: “It is an honor to join Xeltis’ MAB at such a pivotal time in the Company’s development. I am truly excited by Xeltis’ innovative technology which, through its avoidance of the frequent reinterventions and infections associated with current treatment options, has the potential to transform patient outcomes for those with end-stage renal disease.”
Monnie Wasse, MD, MPH, newly appointed member of the Xeltis Medical Advisory Board, added: “I am familiar with the important work of Xeltis, having kept a keen eye on the continual clinical progress of its technology. aXess has an immensely promising medical profile, and I am proud to now be in a position to offer my expertise in interventional nephrology and vascular access to further the clinical development of this innovative technology.”
aXess is a restorative vascular access conduit which enables the creation of new, long-term living vessels for hemodialysis vascular access. It combines the safety and patency of a fistula with the speed to treatment of an AV graft while avoiding the frequent reinterventions and complications, such as infections, associated with current treatment options. Currently, Xeltis is advancing pivotal trials in both the EU and the US for aXess; enrolment was recently completed in the EU while ten patients have now been implanted in the US, marking significant clinical milestones in both regions.
Discover the latest trends and insights—explore the Business Insights Journal for up-to-date strategies and industry breakthroughs!
